PRME Stock Analysis: Prime Medicine, Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 699m USD | 12M Return: 5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.8M
Qual. Beats: 0
Rev. Trend: -26.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 3.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Prime Medicine, Inc. (NASDAQ: PRME) is a clinical-stage biotechnology company developing genetic medicines using its proprietary Prime Editing platform. Headquartered in Cambridge, Massachusetts and founded in 2019, the company went public on the NASDAQ in October 2022 and operates within the U.S. biotechnology sector, a segment focused on translating novel molecular technologies into therapeutic products.
The companys pipeline is centered on rare and monogenic diseases, with its lead candidate PM359 in Phase 1/2 clinical trials for Chronic Granulomatous Disease. Other programs include PM577 for Wilson Disease (preclinical stage) and PM647, which targets liver damage caused by misfolded Z-AAT protein resulting from SERPINA1 gene mutations. Prime Medicine is also pursuing in vivo liver-directed programs and a Cystic Fibrosis program, and maintains research collaborations and license agreements with Bristol Myers Squibb, the Cystic Fibrosis Foundation, the Broad Institute, and Beam Therapeutics.
Prime Editing, the companys core technology, combines a modified Cas domain that locates a target DNA sequence without inducing a double-stranded break with a reverse transcriptase (RT) domain that copies the edited sequence directly into the genome, directed by a prime editing guide RNA (pegRNA). This search-and-replace approach distinguishes Prime Editing from earlier gene editing modalities such as CRISPR-Cas9, and is designed to enable a wider range of precise DNA edits.
- PM359 Phase 1/2 CGD trial data readout
- BMS collaboration milestone payments extend cash runway
- Wilson Disease and liver editing programs advance toward IND
| Net Income: -198.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -2.79 > 1.0 |
| NWC/Revenue: 2.52k% < 20% (prev 311.1%; Δ 2.21k% < -1%) |
| CFO/TA -0.53 > 3% & CFO -156.4m > Net Income -198.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.1m) vs 12m ago 35.31% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.30% > 50% (prev 12.68%; Δ -11.39% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.34 (Total Current Assets 137.9m - Total Current Liabilities 36.3m) / Total Assets 294.7m |
| B: -3.18 (Retained Earnings -937.5m / Total Assets 294.7m) |
| C: -0.64 (EBIT TTM -198.4m / Avg Total Assets 311.4m) |
| D: 0.35 (Book Value of Equity 76.7m / Total Liabilities 218.0m) |
| Altman-Z'' = -12.02 = D |
As of July 08, 2026, the stock is trading at USD 3.99 with a total of 4,126,542 shares traded. Over the past week, the price has changed by +7.26%, over one month by +34.80%, over three months by +17.01% and over the past year by +5.00%.
Current recommended Stop Loss: 3.40 (which is 14.8% or 1.9 ATR below the current price).
Prime Medicine, Common Stock has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy PRME.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7 | 75.9% |
P/S = 173.2745
P/B = 9.1486
Revenue TTM = 4.03m USD
EBIT TTM = -198.4m USD
EBITDA TTM = -190.9m USD
Long Term Debt = 106.0m USD (estimated: total debt 114.5m - short term 8.55m)
Short Term Debt = 8.55m USD (from shortTermDebt, last quarter)
Debt = 114.5m USD (from shortLongTermDebtTotal, last quarter) (leases 114.5m already included)
Net Debt = -21.0m USD (calculated: Debt 114.5m - CCE 135.5m)
Enterprise Value = 678.0m USD (699.0m + Debt 114.5m - CCE 135.5m)
Interest Coverage Ratio = unknown (Ebit TTM -198.4m / Interest Expense TTM 0.0)
EV/FCF = -4.07x (Enterprise Value 678.0m / FCF TTM -166.8m)
FCF Yield = -24.60% (FCF TTM -166.8m / Enterprise Value 678.0m)
FCF Margin = -4.13k% (FCF TTM -166.8m / Revenue TTM 4.03m)
Net Margin = -4.92k% (Net Income TTM -198.4m / Revenue TTM 4.03m)
Gross Margin = unknown ((Revenue TTM 4.03m - Cost of Revenue TTM 49.6m) / Revenue TTM)
Tobins Q-Ratio = 2.30 (Enterprise Value 678.0m / Total Assets 294.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 114.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -156.7m (EBIT -198.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 137.9m / Total Current Liabilities 48.6m)
Debt / Equity = 1.49 (Debt 114.5m / totalStockholderEquity, last quarter 76.7m)
Debt / EBITDA = 0.11 (negative EBITDA) (Net Debt -21.0m / EBITDA -190.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -21.0m / FCF TTM -166.8m)
Total Stockholder Equity = 105.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.69% (Net Income -198.4m / Total Assets 294.7m)
RoE = -188.8% (Net Income TTM -198.4m / Total Stockholder Equity 105.1m)
RoCE = -94.00% (EBIT -198.4m / Capital Employed (Equity 105.1m + L.T.Debt 106.0m))
RoIC = -58.74% (negative operating profit) (NOPAT -156.7m / Invested Capital 266.8m)
WACC = 13.64% (E(699.0m)/V(813.5m) * Re(15.87%) + D(114.5m)/V(813.5m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 15.87% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 30.45%
[DCF] Fair Price = unknown (Cash Flow -166.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.46 | # QB: 0
Revenue Correlation: -26.77 | Revenue CAGR: -28.68% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.25 | Chg30d=-1.08% | Revisions=-38% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.23 | Chg30d=+0.61% | Revisions=-12% | Analysts=12
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=-0.54% | Revisions=-50% | GrowthEPS=+27.1% | GrowthRev=+104.0%
EPS next Year (2027-12-31): EPS=-0.84 | Chg30d=+3.76% | Revisions=+22% | GrowthEPS=+14.8% | GrowthRev=+109.1%
[Analyst] Revisions Ratio: -27% (up=8, down=15)